1. Křepelka P. Jak se liší aktualizovaná „Doporučení k předpisu kombinované hormonální antikoncepce 2005“ a „Medical eligibility criteria for contraceptive use WHO 2004“. Moderní gynekologie a porodnictví 2005; 14 (Suppl 1): 23–27.
2. Betschart J. Oral contraception and adolescent women with insulin‑dependent diabetes mellitus: risks, benefits, and implication for practice. Diabetes Educ 1996; 22: 374–378.
3. ACOG Comittee on Practice Bulletins-Gynecology. Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107: 1453–1472.
4. Girling J, Dornhorst A. Pregnancy and diabetes mellitus. In: Pickup JC, Willams G (eds). Textbook of diabetes. 3rd ed. Oxford UK: Blackwell Science Ltd 2003.
5. Homko CJ, Trout K. Women and diabetes. Nurs Clin North Am 2006; 41: 549–565.
6. Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet Gynecol 2003; 102: 857–868.
7. Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. Lancet 2002; 359: 1690–1692.
8. Clausen TD, Mathiesen E, Ekbom P et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005; 28: 323–328.
9. Grigoryan OR, Grodnitskaya EE, Andreeva EN et al. Contraception in perimenopausal women with diabetes mellitus. Gynecol Endocrinol 2006; 22: 198–206.
10. Petersen KR. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non‑diabetic women and in women with insulin‑dependent diabetes mellitus. Dan Med Bull 2002; 49: 43–60.
11. Damm P, Mathiesen E, Clausen TD et al. Contraception for women with diabetes mellitus. Metab Syndr Relat Disord 2005; 3: 244–249.
12. Creasy GW, Fisher AC, Hall N et al. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. J Reprod Med 2003; 48: 179–186.
13. Weisberg E, Fraser IS, Lacarra M et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception 1999; 59: 311–318.
14. Amiel SA, Caprio S, Sherwin RS et al. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991; 72: 277–282.
15. Darko DA, Dornhorst A, Kennedy G et al. Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. Diabetes Res Clin Pract 2001; 54: 157–164.
16. Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002; 102: 151–166.
17. Shawe J, Lawrenson R. Hormonal contraception in women with diabetes mellitus: special considerations. Treat Endocrinol 2003; 2: 321–330.
18. Chasan-Taber L, Willett WC, Stampfer MJ et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 1997; 20: 330–335.
19. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 2000; 26: 17–26.
20. Petersen KR, Skouby SO, Sidelmann J et al. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin‑dependent diabetes mellitus. Am J Obstet Gynecol 1994; 171: 400–405.
21. Skouby SO, Mølsted-Pedersen L, Kühl C. Low dosage oral contraception in women with previous gestational diabetes. Obstet Gynecol 1982; 59: 325–328.
22. Petersen KR, Skouby SO, Vedel P et al. Hormonal contraception in women with IDDM. Influence on glycometabolic control and lipoprotein metabolism. Diabetes Care 1995; 18: 800–806.
23. Sidney S, Siscovick DS, Petitti DB et al. Myocardial infarction and use of low‑dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998; 98: 1058–1063.
24. Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998; 57: 211–230.
25. Klein BE, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care 1990; 13: 895–898.
26. Curtis KM, Chrisman CE, Peterson HB. WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol 2002; 99: 1100–1112.
27. Monster TB, Janssen WM, de Jong PE et al. Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001; 161: 2000–2005.
28. Ahmed SB, Hovind P, Parving HH et al. Oral contraceptives, angiotensin‑dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005; 28: 1988–1994.
29. Klein BE, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1999; 22: 1984–1987.
30. Damm P, Mathiesen ER, Petersen KR et al. Contraception after gestational diabetes. Diabetes Care 2007; 30 (Suppl 2): S236–S241.
31. Kjos SL, Peters RK, Xiang A et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280: 533–538.
32. Kahn HS, Curtis KM, Marchbanks PA. Effects of injectable or implantable progestin‑only contraceptives on insulin‑glucose metabolism and diabetes risk. Diabetes Care 2003; 26: 216–225.
33. Kim C, Seidel KW, Begier EA et al. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 2001; 161: 1766–1771.
34. Xiang AH, Kawakubo M, Kjos SL et al. Long‑acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care 2006; 29: 613–617.
35. Konje JC, Otolorin EO, Ladipo OA. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 1992; 166: 15–19.
36. Sturridge F, Guillebaud J. A risk‑benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf 1996; 15: 430–440.
37. Rogovskaya S, Rivera R, Grimes DA et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005; 105: 811–815.
38. Visser J, Snel M, Van Vliet HAAM. Hormonal versus non‑hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database of Syst Rev 2006; CD003990.
39. WHO. Medical eligibility criteria for contraceptive use. WHO 2004 online. Available from: http://www.who.int/reproductive-health/ publications/mec/index.htm.
40. Sorensen MB, Collins P, Ong PJ et al. Long‑term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002; 106: 1646–1651.
41. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613.
42. Rossouw JE, Anderson GL, Prentice RL et al. Writing Group for the Women’s Health Initiative Investigators. Risk and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from Women’s Health Initiativr randomized controlled trial. JAMA 2002; 288: 321–333.
43. Lemay A. The relevance of the Women‘s Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can 2002; 24: 683–688.
44. Clarkson TB, Appt SE. Controversies about HRT-lessons from monkey models. Maturitas 2005; 51: 64–74.
45. Saglam K, Polat Z, Yilmaz MI et al. Effects of postmenopausal hormone replacement therapy on insulin resistance. Endocrine 2002; 18: 211–214.
46. Ding EL, Song Y, Malik VS et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta‑analysis. JAMA 2006; 295: 1288–1299.
47. Andersson B, Mårin P, Lissner L et al. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405–411.
48. Kalish GM, Barrett-Connor E, Laughlin GA et al. Postmenopausal Estrogen/Progestin Intervention Trial. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 2003; 88: 1646–1652.
49. Golden SH, Dobs AS, Vaidya D et al. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 1289–1295.
50. Proudler AJ, Felton CV, Stevenson JC. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci (Lond) 1992; 83: 489–494.
51. Raudaskoski T, Tomás C, Laatikainen T. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Acta Obstet Gynecol Scand 1999; 78: 540–545.
52. Saglam K. Insulin resistance and postmenopausal hormone replacement therapy. Metab Syndr Relat Disord 2004; 2: 234–240.
53. Li C, Samsioe G, Borgfeldt C et al. Low‑dose hormone therapy and carbohydrate metabolism. Fertil Steril 2003; 79: 550–555.
54. Andersson B, Mattsson LA, Hahn L et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin‑dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 638–643.
55. Friday KE, Dong C, Fontenot RU. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 48–52.
56. Perera M, Sattar N, Petrie JR et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2001; 86: 1140–1143.
57. Lindheim SR, Notelovitz M, Feldman EB et al. The independent effects of exercise and estrogen on lipids and lipoproteins in postmenopausal women. Obstet Gynecol 1994; 83: 167–172.
58. Seed M, Sands RH, McLaren M et al. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post‑menopausal women. Fam Pract 2000; 17: 497–507.
59. Lasco A, Alvaro S, Frisina N et al. Long‑term transdermal estrogen therapy improves lipid profile but not insulin resistance in healthy postmenopausal women. Diabetes Care 2000; 23: 422–424.
60. Stevenson JC. The metabolic basis for the effects of HRT on coronary heart disease. Endocrine 2004; 24: 239–244.
61. Bonds DE, Lasser N, Qi L et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial. Diabetologia 2006; 49: 459–468.
62. Herrington DM, Reboussin DM, Brosnihan B et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–529.
63. Crook D, Godsland IF, Hull J et al. Hormone replacement therapy with dydrogesterone and 17 beta‑oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997; 104: 298–304.
64. Shadoan MK, Kavanagh K, Zhang L et al. Addition of medroxyprogesterone acetate to conjugated equine estrogens results in insulin resistance in adipose tissue. Metabolism 2007; 56: 830–837.
65. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits – an attempt to interpret the Women’s Health Initiative results. Gynecol Endocriol 2006; 22: 303–317.
66. Cefalu WT, Wagner JD, Bell-Farrow AD et al. The effects of hormonal replacement therapy on insulin sensitivity in surgically postmenopausal cynomolgus monkeys (Macaca fascicularis). Am J Obstet Gynecol 1994; 171: 440–445.
67. Salpeter SR, Walsh JM, Ormiston TM et al. Meta‑analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8: 538–554.
68. Tankó LB, Christiansen C. Effects of 17beta‑oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Intern Med 2005; 258: 544–553.
69. Cooper BC, Burger NZ, Toth MJ et al. Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. Am J Obstet Gynecol 2007; 196: 123–127.
70. Kanaya AM, Herrington D, Vittinghoff E et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progeston Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 1–9.
71. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: consensus opinion of The North American Menopause Society. Menopause 2000; 7: 87–95.
72. Lindheim SR, Presser SC, Ditkoff EC et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664–667.
73. Salpeter SR, Walsh JM, Greyber E et al. Mortality associated with hormone replacement therapy in younger and older women: a meta‑analysis. J Gen Intern Med 2004; 19: 791–804.
74. Hodis HN, Mack WJ, Lobo R. Antiatherosclerosis interventions in women. Am J Cardiol 2002; 90 (Suppl): 17F–21F.
75. Naftolin F, Taylor HS, Karas R et al. The Women’s Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004; 81: 1498–1501.
76. Mihmanli V, Mihmanli I, Atakir K et al. Carotid intima-media thickness in surgical menopause: women who recieved HRT versus who did not. Maturitas 2002; 42: 37–43.
77. Howard BV, Hsia J, Ouyang P et al. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004; 110: 201–206.
78. Anderson GL, Limacher M, Assaf AR et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712.
79. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study. A prospective, observational study. Ann Intern Med 2001; 135: 1–8.
80. Stauffer BL, Hoetzer GL, Smith DT et al. Plasma C‑reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. J Appl Physiol 2004; 96: 143–148.
81. Koh KK, Schenke WH, Waclawiw MA et al. Statin attenuates increase in C‑reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 2002; 105: 1531–1533.
82. Oger E, Alhenc-Gelas M, Lacut K et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 1671–1676.